Correction to: Quality of Life Research (2023) 32:989–1003 10.1007/s11136-022-03327-4
In the original publication of the article, the authors realized that the scores of two dimensions of the EORTC QLQ BR23 (Sexual Function and Sexual Enjoyment) were wrongly reversed while preparing the tables. This mistake affects two lines (Sexual Function and Sexual Enjoyment) of Table 4 and Supplementary Table (1.3.2, 1.3.3, 2.3.2 and 2.3.3). The correct version of Table 4 and the supplementary information are provided in this correction.
Table 4.
Mean scores and standard deviations of EORTC QLQ-BR-23 according to age, Charlson Comorbidity Index, and stage
| All | Age | Comorbidity index | Tumor stage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 40 | 40–65 | > 65 | p value* | 0 | ≥ 1 | p value* | 0 | I | II | III | p value* | ||
| At diagnosis | |||||||||||||
| Body Image | 92.3 (16.7) | 87.5 (20.8) | 92.0 (17.0) | 94.5 (14.4) | 0.003 | 92.4 (16.3) | 92.1 (18.4) | 0.779 | 94.2 (12.6) | 92.6 (16.7) | 91.9 (17.2) | 89.8 (19.8) | 0.258 |
| Sexual Function | 23.5 (26.1) | 31.3 (27.1) | 27.4 (26.6) | 10.6 (19.2) | < 0.001 | 24.9 (25.8) | 18.2 (26.5) | < 0.001 | 24.7 (26.5) | 24.9 (26.1) | 21.1 (25.4) | 21.8 (28.3) | 0.126 |
| Sexual enjoy | 54.6 (29.1) | 59.4 (32.1) | 56.2 (28.8) | 42.5 (26.1) | < 0.001 | 55.3 (28.9) | 50.5 (29.9) | 0.140 | 54.5 (26.6) | 54.8 (28.3) | 53.6 (29.7) | 57 (36.0) | 0.913 |
| Future perspective | 45.9 (31.9) | 36.4 (32.0) | 45.7 (31.7) | 48.8 (32.2) | 0.009 | 45.8 (31.3) | 46.3 (34.2) | 0.822 | 50.3 (29.9) | 45.8 (32.1) | 46.4 (32.4) | 39.2 (31.3) | 0.090 |
| Systemic therapy effects | 12.5 (13.9) | 11.5 (13.9) | 12.7 (14.4) | 12.4 (12.7) | 0.764 | 12.2 (13.8) | 13.6 (14.3) | 0.169 | 12.6 (13.5) | 11.8 (13.2) | 13.2 (14.8) | 14.4 (16.2) | 0.235 |
| Breast symptoms | 13.2 (16.9) | 19.2 (20.4) | 13.4 (16.9) | 11.1 (15.8) | 0.001 | 13.7 (17.2) | 11.0 (15.6) | 0.021 | 13.4 (17.2) | 12.5 (17.2) | 14.4 (16.7) | 12.9 (15.8) | 0.342 |
| Arm symptoms | 8.7 (15.6) | 6.4 (12.5) | 8.4 (14.7) | 10.0 (18.3) | 0.127 | 8.2 (14.7) | 11.0 (18.5) | 0.011 | 7.8 (14.0) | 8.4 (15.5) | 9.6 (15.8) | 8.6 (17.2) | 0.592 |
| Upset hair loss | 24.0 (31.6) | 12.3 (27.7) | 25.6 (33.2) | 23.6 (27.7) | 0.223 | 23.5 (31.4) | 26.7 (33.1) | 0.564 | 11.1 (18.5) | 22.9 (32.8) | 28.6 (32.5) | 33.3 (31.2) | 0.053 |
| At 2-year follow-up | |||||||||||||
| Body Image | 84.6 (24.6) | 79.7 (28.6) | 82.9 (25.8) | 88.8 (21.0) | 0.001 | 84.6 (24.7) | 84.7 (24.4) | 0.956 | 90.1 (18.3) | 86.7 (22.4) | 81.4 (27.0) | 73.5 (33.7) | < 0.001 |
| Sexual Function | 20.9 (23.5) | 29.5 (21.0) | 25 (24.1) | 9.9 (17.9) | < 0.001 | 22.4 (24.0) | 15.4 (21.0) | < 0.001 | 23.8 (24.1) | 21.7 (24.3) | 18.9 (22.5) | 19 (19.8) | 0.163 |
| Sexual enjoy | 50.3 (27.8) | 62.8 (23.7) | 53.2 (27.0) | 34.3 (27.1) | < 0.001 | 51.3 (28.1) | 45.6 (26.2) | 0.070 | 52.8 (26.3) | 51.3 (29.2) | 48.2 (27.1) | 47 (22.6) | 0.518 |
| Future perspective | 59.5 (32.1) | 55.9 (37.4) | 57.1 (31.9) | 65.0 (31.4) | 0.001 | 59.2 (31.9) | 60.6 (33.0) | 0.557 | 66.4 (29.3) | 59.6 (31.6) | 59.1 (32.4) | 48.4 (36.9) | 0.003 |
| Systemic therapy effects | 18.3 (16.5) | 12.2 (11.1) | 18.9 (16.8) | 17.9 (16.1) | 0.056 | 17.7 (16.3) | 20.7 (17.3) | 0.014 | 16.6 (15.4) | 17.8 (15.8) | 19.3 (17.8) | 21.1 (17.8) | 0.171 |
| Breast symptoms | 16.0 (17.8) | 17.4 (19.5) | 17.4 (18.0) | 13.0 (16.9) | 0.001 | 15.8 (16.8) | 16.6 (21.0) | 0.572 | 15.0 (18.5) | 16.0 (17.0) | 16.1 (18.7) | 17.2 (18.5) | 0.859 |
| Arm symptoms | 15.7 (20.3) | 9.5 (15.0) | 16.2 (20.3) | 15.5 (20.8) | 0.157 | 15.0 (19.5) | 18.2 (23.0) | 0.035 | 12.0 (18.0) | 14.2 (19.4) | 18.2 (21.0) | 22.8 (24.8) | < 0.001 |
| Upset hair loss | 31.1 (33.7) | 13.9 (30.0) | 32.0 (33.4) | 31.2 (34.3) | 0.192 | 29.4 (32.6) | 36.9 (36.7) | 0.058 | 22.0 (26.8) | 29.8 (33.4) | 34.4 (34.5) | 42.0 (40.5) | 0.066 |
*EORTC QLQ-BR-23 differences according to age, comorbidity and stage were tested with ANOVA
The original article has been corrected.
Supplementary Information
Below is the link to the electronic supplementary material.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Montse Ferrer, Email: mferrer@imim.es.
the REDISSEC-CaMISS Group:
Mercè Comas, Laia Domingo, Francesc Macià, Marta Roman, Anabel Romero, Teresa Barata, Isabel Diez de la Lastra, Mariola de la Vega, Marisa Bare, Núria Torà, Joana Ferrer, Francesc Castanyer, Carmen Carmona, Susana García, Maximina Martín, Nerea Gonzalez, Maria Amparo Valverde, Alberto Saez, Inma Barredo, Manuel de Toro, Josefa Ferreiro, Jeanette Pérez, Cristina Valcárcel, María del Carmen Padilla, Teresa Téllez, Irene Zarcos, Cristina Churruca, Amaia Perales, Javier Recio, Irune Ruiz, Jose María Urraca, MªJesús Michelena, Julio Moreno, Gaizka Mallabiabarrena, Patricia Cobos, Borja Otero, Javier Gorostiaga, and Itsaso Troya
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.